BMO Capital analyst Sean Dodge initiated coverage of Sotera Health (SHC) with an Outperform rating and $19 price target The macro and industry headwinds that have dragged on Solera’s growth over the last 2-3 years have finally begun to dissipate, which paves the way for a re-acceleration in both revenue and EBITDA growth back toward management’s longer-range 5%-7% and 5%-8% targets, the analyst tells investors in a research note. Ongoing litigation remains a risk, but is already discounted into the current valuation.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health Stockholders Sell 30 Million Shares
- Sotera Health announces offering of 30M shares of common stock for holders
- Sotera Health price target raised to $17 from $15 at Piper Sandler
- Sotera Health price target raised to $16 from $14 at JPMorgan
- Sotera Health price target raised to $20 from $19 at Barclays